- Home
- BIIB vs CRDO Comparison
BIIB vs CRDO Comparison
Compare BIIB & CRDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CRDO
- Stock Information
- Founded
- BIIB 1978
- CRDO 2008
- Country
- BIIB United States
- CRDO Cayman Islands
- Employees
- BIIB N/A
- CRDO N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CRDO Semiconductors
- Sector
- BIIB Health Care
- CRDO Technology
- Exchange
- BIIB Nasdaq
- CRDO Nasdaq
- Market Cap
- BIIB 18.7B
- CRDO 18.9B
- IPO Year
- BIIB 1991
- CRDO 2022
- Fundamental
- Price
- BIIB $154.38
- CRDO $159.06
- Analyst Decision
- BIIB Buy
- CRDO Strong Buy
- Analyst Count
- BIIB 24
- CRDO 13
- Target Price
- BIIB $174.62
- CRDO $133.67
- AVG Volume (30 Days)
- BIIB 1.6M
- CRDO 5.8M
- Earning Date
- BIIB 10-30-2025
- CRDO 12-01-2025
- Dividend Yield
- BIIB N/A
- CRDO N/A
- EPS Growth
- BIIB N/A
- CRDO N/A
- EPS
- BIIB 10.97
- CRDO 0.67
- Revenue
- BIIB $10,065,900,000.00
- CRDO $600,135,000.00
- Revenue This Year
- BIIB $2.97
- CRDO $126.77
- Revenue Next Year
- BIIB N/A
- CRDO $28.02
- P/E Ratio
- BIIB $14.17
- CRDO $243.08
- Revenue Growth
- BIIB 4.77
- CRDO 175.81
- 52 Week Low
- BIIB $110.04
- CRDO $29.09
- 52 Week High
- BIIB $176.95
- CRDO $193.50
- Technical
- Relative Strength Index (RSI)
- BIIB 59.29
- CRDO 50.99
- Support Level
- BIIB $148.90
- CRDO $163.84
- Resistance Level
- BIIB $157.79
- CRDO $178.99
- Average True Range (ATR)
- BIIB 4.78
- CRDO 12.97
- MACD
- BIIB 0.43
- CRDO 0.30
- Stochastic Oscillator
- BIIB 82.77
- CRDO 43.84
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CRDO Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd delivers high-speed solutions to break bandwidth barriers on every wired connection in the data infrastructure market. It provides secure, high-speed connectivity solutions that deliver improved power and cost efficiency as data rates and corresponding bandwidth requirements increase exponentially throughout the data infrastructure market. It has a geographic presence in Hong Kong, the United States, Mainland China, Taiwan, and the Rest of the World.